92 related articles for article (PubMed ID: 15831773)
21. Chlamydia pneumoniae induces macrophage-derived foam cell formation via PPAR alpha and PPAR gamma-dependent pathways.
Mei CL; He P; Cheng B; Liu W; Wang YF; Wan JJ
Cell Biol Int; 2009 Mar; 33(3):301-8. PubMed ID: 19114110
[TBL] [Abstract][Full Text] [Related]
22. Peroxisome proliferator-activated receptor agonists modulate heart function in transgenic mice with lipotoxic cardiomyopathy.
Vikramadithyan RK; Hirata K; Yagyu H; Hu Y; Augustus A; Homma S; Goldberg IJ
J Pharmacol Exp Ther; 2005 May; 313(2):586-93. PubMed ID: 15671204
[TBL] [Abstract][Full Text] [Related]
23. S26948, a new specific peroxisome proliferator activated receptor gamma modulator improved in vivo hepatic insulin sensitivity in 48 h lipid infused rats.
Sohn KA; Cruciani-Guglielmacci C; Kassis N; Clément L; Ouali F; Caüzac M; Lebègue N; Berthelot P; Caignard DH; Pégorier JP; Renard P; Dacquet C; Ktorza A; Magnan C;
Eur J Pharmacol; 2009 Apr; 608(1-3):104-11. PubMed ID: 19250932
[TBL] [Abstract][Full Text] [Related]
24. Chronic activation of peroxisome proliferator-activated receptor-alpha with fenofibrate prevents alterations in cardiac metabolic phenotype without changing the onset of decompensation in pacing-induced heart failure.
Labinskyy V; Bellomo M; Chandler MP; Young ME; Lionetti V; Qanud K; Bigazzi F; Sampietro T; Stanley WC; Recchia FA
J Pharmacol Exp Ther; 2007 Apr; 321(1):165-71. PubMed ID: 17215446
[TBL] [Abstract][Full Text] [Related]
25. Discordance between intramuscular triglyceride and insulin sensitivity in skeletal muscle of Zucker diabetic rats after treatment with fenofibrate and rosiglitazone.
Nadeau KJ; Ehlers LB; Aguirre LE; Reusch JE; Draznin B
Diabetes Obes Metab; 2007 Sep; 9(5):714-23. PubMed ID: 17697064
[TBL] [Abstract][Full Text] [Related]
26. PPAR-alpha agonist fenofibrate induces renal CYP enzymes and reduces blood pressure and glomerular hypertrophy in Zucker diabetic fatty rats.
Zhao X; Li LY
Am J Nephrol; 2008; 28(4):598-606. PubMed ID: 18277067
[TBL] [Abstract][Full Text] [Related]
27. A novel peroxisome proliferator--activated receptor alpha/gamma dual agonist ameliorates dyslipidemia and insulin resistance in prediabetic rhesus monkeys.
Ding SY; Tigno XT; Braileanu GT; Ito K; Hansen BC
Metabolism; 2007 Oct; 56(10):1334-9. PubMed ID: 17884441
[TBL] [Abstract][Full Text] [Related]
28. The effect of peroxisome proliferator-activated receptors alpha (PPARalpha) agonist, fenofibrate, on lipid peroxidation, total antioxidant capacity, and plasma paraoxonase 1 (PON 1) activity.
Bełtowski J; Wójcicka G; Mydlarczyk M; Jamroz A
J Physiol Pharmacol; 2002 Sep; 53(3):463-75. PubMed ID: 12369742
[TBL] [Abstract][Full Text] [Related]
29. An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers.
Penn R; Williams RX; Guha-Ray DK; Sawyers WG; Braun SL; Rains KT
Clin Ther; 2006 Jan; 28(1):45-54. PubMed ID: 16490579
[TBL] [Abstract][Full Text] [Related]
30. Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease.
Hong XZ; Li LD; Wu LM
Clin Exp Pharmacol Physiol; 2007; 34(1-2):27-35. PubMed ID: 17201732
[TBL] [Abstract][Full Text] [Related]
31. Effects of fenofibrate on lipid metabolism in adipose tissue of rats.
Ferreira AV; Parreira GG; Green A; Botion LM
Metabolism; 2006 Jun; 55(6):731-5. PubMed ID: 16713430
[TBL] [Abstract][Full Text] [Related]
32. Fenofibrate and pioglitazone do not ameliorate the altered vascular reactivity in aorta of isoproterenol-treated rats.
Fukuda LE; Davel AP; Verissimo-Filho S; Lopes LR; Cachofeiro V; Lahera V; Rossoni LV
J Cardiovasc Pharmacol; 2008 Nov; 52(5):413-21. PubMed ID: 19033820
[TBL] [Abstract][Full Text] [Related]
33. Nonalcoholic hepatic steatosis in Zucker diabetic rats: spontaneous evolution and effects of metformin and fenofibrate.
Forcheron F; Abdallah P; Basset A; del Carmine P; Haffar G; Beylot M
Obesity (Silver Spring); 2009 Jul; 17(7):1381-9. PubMed ID: 19553925
[TBL] [Abstract][Full Text] [Related]
34. Attenuation of cardiac dysfunction by a PPAR-alpha agonist is associated with down-regulation of redox-regulated transcription factors.
Ichihara S; Obata K; Yamada Y; Nagata K; Noda A; Ichihara G; Yamada A; Kato T; Izawa H; Murohara T; Yokota M
J Mol Cell Cardiol; 2006 Aug; 41(2):318-29. PubMed ID: 16806263
[TBL] [Abstract][Full Text] [Related]
35. Activation of peroxisome proliferator-activated receptor-alpha by fenofibrate prevents myocardial dysfunction during endotoxemia in rats.
Jozefowicz E; Brisson H; Rozenberg S; Mebazaa A; Gelé P; Callebert J; Lebuffe G; Vallet B; Bordet R; Tavernier B
Crit Care Med; 2007 Mar; 35(3):856-63. PubMed ID: 17255874
[TBL] [Abstract][Full Text] [Related]
36. Effect of GCP-02, a PPARalpha/gamma dual activator, on glucose and lipid metabolism in insulin-resistant mice.
Wang ZJ; Liu Q; Li PP; Zou CH; Shen ZF
Eur J Pharmacol; 2008 Feb; 580(1-2):277-83. PubMed ID: 18048028
[TBL] [Abstract][Full Text] [Related]
37. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus.
Terra SG; Francone OL; Contant CF; Gao X; Lewin AJ; Nguyen TT
Am J Cardiol; 2008 Aug; 102(4):434-9. PubMed ID: 18678301
[TBL] [Abstract][Full Text] [Related]
39. Metabolic effects of various antidiabetic and hypolipidaemic agents on a high-fat diet and multiple low-dose streptozocin (MLDS) mouse model of diabetes.
Arulmozhi DK; Kurian R; Bodhankar SL; Veeranjaneyulu A
J Pharm Pharmacol; 2008 Sep; 60(9):1167-73. PubMed ID: 18718120
[TBL] [Abstract][Full Text] [Related]
40. Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients.
Rosenson RS
Obesity (Silver Spring); 2009 Mar; 17(3):504-9. PubMed ID: 19023279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
